arrow
C

Costanza Lamperti

Fondazione IRCCS Istituto Neurologico C. Besta
H指数:46
被引数:7,517

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements

MELAS和卒中样发作的诊断标准与管理:基于共识的声明

2026-04-180
OAAI
The return of metabolism: biochemistry and physiology of glycolysis

代谢的回归:糖酵解的生化和生理学 [J]

2025-11-011
OAAI
Amino acid supplementation in patients affected by leukoencephalopathies associated with mitochondrial aminoacyl tRNA synthetase pathogenic variants: Pilot clinical trial in adults and review of literature

氨基酸补充在受累于与线粒体氨基酰tRNA合成酶致病性变异相关脱髓鞘脑白质病变患者中的应用:成人初步临床试验及文献综述

2025-10-060
PRE
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial
2024-11-211
OAAI
Deoxyguanosine kinase deficiency: natural history and liver transplant outcome
2024-05-063
OAAI
Digenic Leigh syndrome on the background of the m.11778G>A Leber hereditary optic neuropathy variant

以m.11778G为背景的Digenic Leigh综合征> Leber遗传性视神经病变变体

BRAIN
IF11.7
2024-03-134
OAAI
Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy
2024-02-018
OAAI
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy The MMPOWER-3 Randomized Clinical Trial
2023-07-1820
OAAI
Bi-allelic LETM1 variants perturb mitochondrial ion homeostasis leading to a clinical spectrum with predominant nervous system involvement
2022-09-016
OAAI
Bi-allelic variants in OGDHL cause a neurodevelopmental spectrum disease featuring epilepsy, hearing loss, visual impairment, and ataxia
2021-12-0115
OAAI
Clinical, imaging, biochemical and molecular features in Leigh syndrome: a study from the Italian network of mitochondrial diseases
2021-10-0923
OAAI